Fintel reports that on July 1, 2025, Scotiabank downgraded their outlook for INmune Bio (NasdaqCM:INMB) from Sector Outperform to Sector Underperform. Analyst Price Forecast Suggests 1,036.95% Upside ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

Moss stated, "For our CORDStrom program, we have a number of significant events in front of us. In Q4, we'll present additional data from the trial. In mid-'26, we expect to file a marketing ...

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...

The company’s reliance on future clinical trial results introduces significant uncertainty regarding the potential success of its drug candidates, highlighting risks that may deter investors. The ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...

INmune Bio's CORDStrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 ...

A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price. As INmune CEO Raymond Tesi, M.D., said on an earnings call ...

Reduction of Metastatic Spread: The addition of INB03 significantly reduced the incidence of metastases to brain, lung, and liver (quantified by ex-vivo IVIS luminescence imaging). Notably, it further ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against ...

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience ...

INmune Bio Inc. (NASDAQ:INMB) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, per data from Benzinga Pro. On Thursday, INmune Bio ...